NL repository
menu
검색
Library
Browse
Communities & Collections
By Date
Authors
Titles
Subject
My Repository
My Account
Receive email updates
Edit Profile
DSpace at EWHA
의료원
의료원
Journal papers
View : 10 Download: 0
Stem cell therapy for interstitial cystitis/bladder pain syndrome
Title
Stem cell therapy for interstitial cystitis/bladder pain syndrome
Authors
Shin
;
Jung Hyun
;
Park
;
Ju Hyun
;
Ryu
;
Chae-Min
;
Dong-Myung
;
Choo
;
Myung-Soo
Ewha Authors
신정현
SCOPUS Author ID
신정현
Issue Date
2024
Journal Title
LUTS: Lower Urinary Tract Symptoms
ISSN
1757-5664
Citation
LUTS: Lower Urinary Tract Symptoms vol. 16, no. 4
Keywords
bladder pain syndrome
;
clinical trial
;
interstitial cystitis
;
mesenchymal stem cell
;
stem cell therapy
Indexed
SCIE; SCOPUS
Document Type
Review
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic disease with limited treatment options. Current multidisciplinary approach targeting bladder inflammation and urothelial dysfunction has limited durable effect that major surgery is ultimately required for both Hunner and non-Hunner type IC. Various investigational attempts are underway to avoid such operations and preserve the urinary bladder. Stem cell therapy is a fascinating option for treating chronic illnesses. Stem cells can self-renew, restore damaged tissue, and have paracrine effects. The therapeutic efficacy and safety of stem cell therapy have been demonstrated in numerous preclinical models, primarily chemically induced cystitis rat models. Only one clinical trial (phase 1 study) has investigated the safety of human embryonic stem cell-derived mesenchymal stem cells in three Hunner-type IC patients. Under general anesthesia, participants underwent cystoscopic submucosal stem cell injection (2.0 × 107 stem cells/5 mL). No safety issues were reported up to 12 months of follow-up and long-term follow-up (up to 3 years). Although there were variations in therapeutic response, all patients reported significant improvement in pain at 1 month postoperatively. One patient underwent fulguration of the Hunner lesion after the trial, but others reported an overall improvement in pain. The analysis on phase 1/2a trial which had several modifications in protocol is currently ongoing. Despite several limitations that need to be overcome, stem cell therapy could be a potential therapeutic option for treating IC/BPS. Clinical outcome on phase 1/2a trial is important and might provide more insight into the clinical application of stem cell therapy for IC/BPS. © 2024 John Wiley & Sons Australia, Ltd.
DOI
10.1111/luts.12527
Appears in Collections:
의료원
>
의료원
>
Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML
Show full item record
Find@EWHA
트윗하기
BROWSE
Communities & Collections
By Date
Authors
Titles
Subject